Raymond Wang
Pediatrics · Orange, CANPI 1508914458
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.7%), education and speaking fees — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 71.3% of it on its own, with 4 other manufacturers making up the rest. Among pediatrics clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $1260.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$22K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Sanofi$3K
- Mirum Pharmaceuticals, Inc.$500
- Travere Therapeutics, Inc.$2
Across 264 payments — averaging $4264.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$693K
- Ultragenyx Pharmaceutical Inc.$231K
- Mallinckrodt Enterprises LLC$63K
- Sanofi US Services Inc.$47K
- Mallinckrodt Hospital Products Inc.$46K
- Takeda Pharmaceuticals U.S.A., Inc.$36K
- plus $11K from 2 others
What the payments were for
- Consulting fees$11,41238%
- Speaking & faculty fees$7,55025%
- Travel & lodging$3,20811%
- Food & beverage$3391%
- Education$7,73426%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 16 | $21,578 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $4,945 |
| Sanofi | 2 | $3,218 |
| Mirum Pharmaceuticals, Inc. | 1 | $500 |
| Travere Therapeutics, Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,243 in reported general payments places this provider in the 95th percentile of 5,539 pediatrics providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VimizimElosulfase Alfa | 14 | $815,485 |
| GalafoldMigalastat Hcl | 13 | $383,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Vimizim | $21,578 | $815,48514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,539 pediatrics providers in California.
Other pediatrics in Orange
- Nina HwangOrange$108K
- Nancy KuntzOrange$103K
- Laurene MascolaLos Angeles$451K
- Tonya ChaffeeSan Francisco$359K
- Anthony PortaleSan Francisco$354K
- David KesslerSan Francisco$335K
- Lawrence SherRolling Hills Estates$297K
- Steven BlackOakland$228K
- Jonathan StroberSan Francisco$164K
- Hasmukh AminBakersfield$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.